Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Annovis Bio, Inc. logo — Transforming how we treat Alzheimer’s, Parkinson’s, and beyo...

Annovis Bio, Inc.

Transforming how we treat Alzheimer’s, Parkinson’s, and beyond.

Founded 2008 United States Malvern, United States 12 employees IPO Total: $121.02M Biotechnology, Health and Wellness +1

General Information

Company Name Annovis Bio, Inc.
Founded Year 2008
Location United States Malvern, United States +1
Founders / Decision Makers
Team member
Employees 12
Industries Biotechnology, Health and Wellness, Platforms
Funding Stage IPO
Social

Get notified when Annovis Bio, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Annovis Bio, Inc.

Annovis Bio, Inc. is a promising player in the biotechnology industry, with a compelling slogan emphasizing the urgency for a new approach in treating Alzheimer’s, Parkinson’s, and related neurodegenerative diseases. Established in 2008 and headquartered in the United States, the company has recently secured a $7.50MPost-IPO Equity investment as of 31 October 2023. Annovis is focused on developing novel drug therapies for chronic and acute neurodegeneration, with their lead compound, ANVS-401, showing promising results in both preclinical and clinical studies. ANVS-401, a small, once a day, orally administered, brain penetrant inhibitor of neurotoxic proteins, has demonstrated potential as the first drug to interfere with the underlying mechanism of neurodegeneration. The compound has undergone extensive evaluation in 19 animal studies at renowned institutions such as the Karolinska Institute, Columbia University, and Harvard University. Human clinical trials have also been conducted, including safety studies in 120 healthy volunteers and a proof-of-concept study in five MCI patients, showing promising clinical signals. The company is currently engaged in a Phase 2a study in AD patients in collaboration with the Alzheimer Disease Cooperative Study (ADCS) group, and plans to initiate a second Phase 2a proof-of-concept study of ANVS-401 in the first quarter of 2020 with 50 PD patients. Annovis is driven by the belief that addressing Alzheimer’s and Parkinson’s represents significant unmet medical needs in the aging U.S. population, presenting potentially lucrative markets. Their aspiration is to demonstrate the efficacy of ANVS-401 in both indications, signaling a promising future for the company.

Taxonomy: Annovis Bio, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, ANVS-401, Posiphen, BNC, clinical stage, drug platform company, neurotoxic proteins, Phase 2a study, neurological disorders, brain penetrant inhibitor, traumatic brain injury, stroke

Funding Rounds & Investors (13)

View All
Funding Stage Amount Investors Lead Investors Date
Post Ipo Equity •••••• - 01 May 2026
Post Ipo Equity •••••• - 01 Oct 2025
Post Ipo Equity •••••• - 01 Feb 2025
Post Ipo Equity •••••• - 01 Apr 2023
Post Ipo Equity •••••• - 01 May 2021

View All 13 Funding Rounds

Annovis Bio, Inc. Alternatives & Competitors

Annovis Bio, Inc. vs
Asceneuron SA
Asceneuron SA Switzerland

Targeting the root cause of neurodegeneration

Series C
20 employees
Biotechnology, Health Care
Annovis Bio, Inc. vs
AXON Neuroscience
AXON Neuroscience Slovakia

Independent clinical stage biotech company.

31 employees
Health Care, Information Technology
Annovis Bio, Inc. vs
ProMIS™ Neurosciences, Inc.
ProMIS™ Neurosciences, Inc. United States

Precision therapeutics for protein misfolding disorders, including Alzheimer's, ALS and Parkinson’s...

Unknown
22 employees
Biotechnology, Health Care

FAQ About Annovis Bio, Inc.

Transforming how we treat Alzheimer’s, Parkinson’s, and beyond.
Annovis Bio, Inc. was founded in 2008.
Annovis Bio, Inc. is headquartered in Malvern, United States.
Annovis Bio, Inc. operates in the following industries: Biotechnology, Health and Wellness, Platforms.
Annovis Bio, Inc. has approximately 12 employees.
Annovis Bio, Inc. has completed 13 funding rounds, raising a total of $121.02M. The latest funding stage is IPO.
Top alternatives and competitors to Annovis Bio, Inc. include Asceneuron SA, AXON Neuroscience, ProMIS™ Neurosciences, Inc., SeNostic GmbH, Vertero Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Annovis Bio, Inc. and Asceneuron SA are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Annovis Bio, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes